Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Potassium-Retaining Diuretics: Amiloride
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
Pharmaceutical approval update.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Epstein-Barr virus: an important vaccine target for cancer prevention.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Complementary and alternative medicine in multiple sclerosis.
Multiple sclerosis and breast cancer.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.
Demyelination: the role of reactive oxygen and nitrogen species.
Cortical lesion load associates with progression of disability in multiple sclerosis.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide

Pages